uniQure Announces Dosing of First Patients in Europe Open-Label Trial of AMT-130katie8288Feb 7, 20220 min read
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Comments